الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 70 |  |  |
| | | from | 70 | | |
Abstract
Asymptomatic Bacteriuria (ASB) is defined as the presence of actively multiplying bacteria, which is greater than 105/ml of urine within the urinary tract, excluding the distal urethra, at a time when the patient has no symptoms of a UTI.
ASB can be found in both pregnant and non–pregnant women. The prevalence of ASB was found to be 12 % in pregnant women.
Pregnancy enhances the progression from ASB to symptomatic bacteruria, which could lead to acute pyelonephritis in 20-50% of cases and to adverse obstetric outcomes such as prematurity, postpartum hypertensive disease, anaemia, UTIs, and higher foetal mortality rates, if it is left untreated.
Urine culture is the gold standard screening technique for ASB which occurs during pregnancy. The predominant organism that causes UTIs during pregnancy is Escherichia coli, which accounts for 80-90% of infections. Other related microorganisms include other Enterobacteriae (Klebsiella, Enterobacter, Proteus), Staphylococcus Aureus, Staphylococcus Saprophyticus, Enterococcus Faecalis)
Screening for and treatment of asymptomatic bacteriuria in pregnancy has become a standard of obstetric care and most antenatal guidelines include routine screening for asymptomatic bacteriuria
Urine samples were collected by standard mid-stream “clean catch” method from all the pregnant women, in sterile, wide mouthed containers and sent to microbiology laboratory for culture and sensitivity test. Two weeks after treatment, another culture is done to assess the cure and recurrence rate of ASB.
There is no consensus in the literature as to the optimal timing and screening frequency for asymptomatic bacteriuria. The authors concluded the risk of acquisition was the highest between the 9th and 17th week and that the 16th gestational week was the optimal time for screening because treatment at that time would provide the greatest number of bacteriuria-free gestational weeks.
The most severe complication in pregnant women with ASB is acute pyelonephritis. Its incidence rate is 20-30 % with a risk of urosepsis, higher foetal and maternal morbidity.
In this study we gave oral cefixime (ximacef) to pregnant women with ASB who are sensitive to this drug. Out of 500 pregnant women, sixty patient were with ASB. There were ten patients who are insensitive to ximacef and fifty were sensitive to it. The sensitive patients were divided into two groups, one group (25 case) have taken seven days of oral ximacef 400 mg/day (one capsule per day) and another group (25 case) take three days of the drug.
After study and according to our results we concluded that seven days therapy is better and effective than three days therapy.